The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | MPN transformation and treatment options
In this video, Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the dire outcomes associated with transformation in myeloproliferative neoplasms (MPNs), and the need for better therapeutic options for these patients. Dr Rampal first draws focus on the current treatment regimens available for these patients, including the need for allogeneic stem cell transplant (allo-SCT) when administering intensive chemotherapy. Following this, Dr Rampal outlines some of the results seen with the more recent use of hypomethylating agents (HMAs), either as a monotherapy or in combination with ruxolitinib or venetoclax. To conclude, Dr Rampal explains that better solutions need to be found, and mentions the potential benefit of using IDH2 inhibitors in patients with IDH2-mutant disease. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
